STOCK TITAN
  1. Home
  2. News
  3. CRMD

CorMedix Inc. - CRMD STOCK NEWS

Welcome to our dedicated page for CorMedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on CorMedix stock.

CorMedix Inc. (Nasdaq: CRMD), headquartered in Bridgewater, NJ, is a biopharmaceutical company dedicated to the development and commercialization of therapeutic products aimed at preventing and treating infectious and inflammatory diseases. The company's flagship product, DefenCath®, is targeted towards reducing the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure undergoing chronic hemodialysis through a central venous catheter.

Recently, CorMedix announced its financial results for the fourth quarter and full year ended December 31, 2023, during a conference call held on March 12, 2024. The company showcased significant advancements in their product pipeline and continued efforts to expand the market reach of DefenCath®. This includes ongoing clinical trials and strategic partnerships aimed at enhancing patient safety and treatment efficacy.

DefenCath®, which combines taurolidine and heparin, has been pivotal in addressing the critical need for infection control in hemodialysis patients. The product has shown promising results in reducing bloodstream infections and is poised to make a substantial impact in the healthcare sector. CorMedix remains committed to research and development, with an emphasis on innovation and quality.

For more detailed information about DefenCath®, including safety information, prescribing guidelines, and potential adverse effects, professionals and patients are encouraged to review the full prescribing information available on the company's website.

CorMedix's financial health remains robust, bolstered by strategic investments and a clear focus on growth and sustainability. The company continues to engage with investors and stakeholders through transparent communication and regular updates on their progress.

For latest updates and detailed news about CorMedix Inc., investors and interested parties can visit the company's website and review recent press releases and financial reports.

News

CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

Rhea-AI Summary
CorMedix Inc. (CRMD) announces acceptance of two abstracts for presentation at the SHEA conference. The first abstract showcases taurolidine's broad antimicrobial activity against various bacteria, including NTM and fungal isolates. The second abstract highlights outcomes and economics of hospital-acquired bloodstream infections in hemodialysis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.02%
Tags
none
-
News

CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

Rhea-AI Summary
CorMedix Inc. (CRMD) secures a 5-year commercial supply contract with ARC Dialysis, for DefenCath®, a product approved under LPAD. The agreement aims to prevent infections in hemodialysis patients, showcasing CorMedix's commitment to innovation and partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
News

CorMedix Inc. to Present at the Needham Annual Healthcare Conference

Rhea-AI Summary
CorMedix Inc. (CRMD) will participate in the Needham 23rd Annual Healthcare Conference, presenting at a fireside chat and investor meetings virtually on April 8 – 11, 2024. The company focuses on developing therapeutic products for life-threatening conditions. Investors can access the webcast and replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences
News

CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Rhea-AI Summary
CorMedix Inc. (CRMD) announces FDA approval for DefenCath, a catheter lock solution to reduce infections in kidney failure patients on hemodialysis. The company is preparing for commercial launch and has a strong financial position with $76.0 million in cash and short-term investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
earnings
-
News

CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024

Rhea-AI Summary
CorMedix Inc. (CRMD) will release its Q4 and full-year 2023 financial results on March 12, 2024, followed by a corporate update conference call. The company focuses on developing therapeutic products for life-threatening conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
conferences earnings
-
News

CorMedix Inc. Announces Commercial and Reimbursement Updates

Rhea-AI Summary
CorMedix Inc. announced updates related to the anticipated launch of DefenCath, a therapeutic product for the prevention and treatment of life-threatening diseases. The Center for Medicare & Medicaid Services (CMS) has determined that DefenCath will be eligible for reimbursement under the ESRD PPS, allowing CorMedix to submit an application for a Transitional Drug Add-On Payment (TDAPA) for five years of additional payment reimbursement to outpatient providers. The list price for DefenCath has been set at $249.99 per 3ml vial, with a commitment to reduce the list price if eligible for Medicare Part B reimbursement. CorMedix also received a New Technology Add-On Payment (NTAP) for inpatient reimbursement and plans to launch commercialization on April 15, 2024 for inpatient and July 1, 2024 for outpatient, contingent upon CMS approval and implementation of the TDAPA application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.27%
Tags
none
News

CorMedix Inc. Announces Commercial and Operational Updates

Rhea-AI Summary
CorMedix Inc. (CRMD) announces commercial and operational updates related to the anticipated launch of DefenCath®. The company submitted an HCPCS application for a J-Code to CMS for DefenCath, with a commercial availability estimate of April 15, 2024 for the inpatient setting and no sooner than July 1, 2024 for the outpatient setting. Significant interest from providers has been received, with several large and medium-sized health systems committing to put DefenCath through their P&T formulary processes in 2024. CorMedix believes it has sufficient resources to fund the commercial launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.49%
Tags
none
-
News

CorMedix Inc. Announces Appointment of Chief Legal Officer

Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD) appoints Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, while Dr. Phoebe Mounts will no longer serve as the Company’s General Counsel. Ms. Zelnick Kaufman brings over two decades of legal, compliance, and operations experience in the life sciences industry, having served in leadership roles at Akorn Pharmaceuticals and Amneal Pharmaceuticals. CorMedix aims to launch DefenCath over the coming months and transition to a commercial stage entity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
management
-
News

CorMedix Inc. Announces Partnership With The Leapfrog Group

Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD) joins The Leapfrog Group's Partners Advisory Committee to advocate for patient safety and infection prevention. The partnership aims to advance initiatives for patient safety and well-being, shaping the organization's long-term strategic vision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.27%
Tags
partnership
News

CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

Rhea-AI Summary
CorMedix Inc. (Nasdaq: CRMD) announced FDA approval of DefenCath, the first FDA-approved antimicrobial catheter lock solution in the U.S. to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is expected to be available in Q1 2024. The approval was based on a Phase 3 clinical study showing up to a 71% reduction in CRBSI risk. Edward V. Hickey, III, President of the American Association of Kidney Patients, praised the approval as a meaningful moment for patients and their healthcare providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.39%
Tags
fda approval

FAQ

What is the current stock price of CorMedix (CRMD)?

The current stock price of CorMedix (CRMD) is $8.57 as of December 20, 2024.

What is the market cap of CorMedix (CRMD)?

The market cap of CorMedix (CRMD) is approximately 521.2M.

What does CorMedix Inc. specialize in?

CorMedix Inc. specializes in developing and commercializing therapeutic products to prevent and treat infectious and inflammatory diseases.

What is DefenCath®?

DefenCath® is a product aimed at reducing catheter-related bloodstream infections in hemodialysis patients using a central venous catheter.

Where is CorMedix Inc. headquartered?

CorMedix Inc. is headquartered at 745 Route 202-206, Suite 303, Bridgewater, NJ, United States.

How did CorMedix Inc. perform in the fourth quarter of 2023?

CorMedix Inc. announced positive financial results for the fourth quarter and full year ended December 31, 2023, highlighting significant advancements and continued growth.

Who can use DefenCath®?

DefenCath® is indicated for adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter to reduce the incidence of catheter-related bloodstream infections.

What are the potential side effects of DefenCath®?

Common side effects include hemodialysis catheter malfunction, hemorrhage, bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia.

How can safety concerns about DefenCath® be reported?

Safety concerns can be reported to CorMedix Inc. at 1-888-424-6345 or to the FDA at 1-800-FDA-1088 or through the FDA's MedWatch website.

What recent events did CorMedix Inc. announce?

CorMedix recently announced financial results for the fourth quarter and full year ended December 31, 2023, and provided updates on their business and product pipeline during a conference call on March 12, 2024.

Who is the investor contact for CorMedix Inc.?

The investor contact is Dan Ferry, Managing Director at LifeSci Advisors. He can be reached at (617) 430-7576 or via email at daniel@lifesciadvisors.com.

Where can I find more detailed information about DefenCath®?

Detailed information about DefenCath®, including prescribing guidelines and safety information, can be found on the CorMedix website.

Stock CRMD logo
CorMedix Inc.

Nasdaq:CRMD

CRMD Rankings

#3068 Ranked by Market Cap
N/A Ranked by Dividends

CRMD Stock Data

521.21M
60.08M
0.98%
31.94%
11.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BERKELEY HEIGHTS